As lately shown by in vitro and in vivo experiments, up-regulated GBP1 expression is associated with poor prognosis in patients with NSCLC and seems to contribute to erlotinib resistance, while decreased GBP1 expression seems to have the opposite effect. Here, GBP1 is linked to non-small cell lung carcinoma.